Kinase Profiling Inhibitor Database

This is a searchable database of specificities of 243 commonly used signal transduction inhibitors. These results have been provided by the International Centre for Kinase profiling within the MRC Protein Phosphorylation Unit at the University of Dundee.
We strongly recommend undertaking kinase profiling of any kinase inhibitor to be used in a biological experiment. It is essential to have a good feel for the specificity of the kinase inhibitor you are working with in order to be able to properly interpret your data.
If you have additional kinase inhibitors that you would like the International Centre for Kinase profiling team to profile for you please contact us here for further details.
If you have any feedback or suggestions on how to improve this resource we welcome your input. Pass on your ideas to us here.

Inhibitor Structure Image Brutto MW Target Reference Reference 2
NVP-BEZ 235 C30H25Cl2N5O 542.46 PI3K, Akt, mTOR Maira S. Stauffer F. (2008) Mol. Cancer. Ther. 7 1851-1863.
OSU-03012 C26H19F3N4O 460.45 PDK1 Zhu J. (2004) Cancer Res. 64(12) 4309-18
OTSSP167 C25H28Cl2N4O2 487.42 MELK
Parthenolide C15H20O3 248.32 IKKβ Kwok B.H. (2001) Chem. Biol. 8 759-766
PCI-32765 (Ibrutinib) C25H24N6O2 440.5 Btk Honigberg L.A. (2010) Proc Natl Acad Sci 107 13075-13080
PD 0325901 C16H14F3IN2O4 482.19 MEK1 Bain J. (2007) Biochem J. 408 297–315. Barrett SD. (2008) Bioorg. Med. Chem. Lett. 18 6501-6504.
PD 0325901-Cl (CI-1055-R) C16H14O4N2F2ClI 498.65 MEK1
PD 0325901-Cl (CI-1055-Racemic mix of isomers) C16H14O4N2F2ClI 498.65 MEK1
PD 0325901-Cl (CI-1055-S) C16H14O4N2F2ClI 498.65 MEK1
PD 0332991 C24H30ClN7O2 483.99 CDK4, CDK6 Toogood P.L. (2005) J.Med.Chem. 48 2388-2406.
PD 184352 (CI-1040) C17H14ClF2IN2O2 478.66 MEK1, Yes1, ERK1 Mayes PA. (2013) Int J Cancer. E149-57
PF3644022 C21H18N4OS 374.46 MAPKAPK2 Mourey (2010) J.Pharmacol.Exp.Ther. 333 797
PF4708671 C19H21F3N6 390.41 S6K1 Pearce (2010) Biochem.J. 431 245
PI-103 C19H16N4O3 348.36 PI3K Samuels Y. (2004) Science 304 554
Piceatannol C14H12O4 244.2 PKA, SYK Wang B.H. (1998) Planta Med. 64 195 Keely P.J. and Parise L.V. (1996) J. Biol. Chem. 271 26668
Pirfenidone C12H11NO 185.23 Antifibrotic agent, SAPK Kehrer and Margolin (1997) Toxicol. Lett. 90 125 Iyer (1999) J.Pharmacol.Exp.Ther. 289 211
PKR Inhibitor C13H8N4OS 268.3 PKR Ingrand S (2007) FEBS Lett. 581(23):4473-8
PLX 4032 (Vemurafenib) C23H18ClF2N3O3S 489.92 B-RAF Bollag G. (2010) Nature 467 596-9
PLX 4720 (Raf Kinase Inhibitor V) C17H14ClF2N3O3S 413.83 B-Raf Tsai J. (2008) Proc Natl Acad Sci USA. 3041-6
PP1 C16H19N5 281.36 Src Hanke (1996) J.Biol.Chem. 271 695 Liu (1999) Chem.Biol. 6 671
PP2 C15H16ClN5 301.77 Src Kirihara T. (2013) Exp Eye Res. S0014
PP242 C16H16N6O 308.3 mTOR Feldman ME (2009) PLoS Biol 7(2)
PP3 C11H9N5 211.22 Src Hou (2007) Neurosci Lett 420 235
Princeton's TrkA inhibitor compound 20h C24H24BrF3N6O4S2 661.52 Trk A Kim S.H. Tokarski J.S. (2008) Bioorg. Med. Chem. Lett. 18 634-639
PRT062607 C19H23N9O 393.45 SYK Spurgeon S.E. (2013) J. Pharmacol Exp Ther. 2013 Feb. 344(2) 378-387
PS-1145 C17H11ClN4O 322.75 IKK Castro A.C. (2003) Bioorg. Med. Chem. Lett. 13 2419-2422.
Purvalanol A C19H25ClN6O 388.9 cyclin-dependent kinases Gray N.S. (1998) Science 281 533
Purvalanol B C20H25ClN6O3 432.9 CDK
QNZ C22H20N4O 356.4 NF-κB
Quercetagetin C15H10O8 318.3 PIM1 Holder S. (2007) Mol. Cancer Ther. 6 163
R-406 C23H24FN5O5 469.46 SYK Braselmann S. (2006) J Pharmacol Exp Ther. 319(3) 998-1008
Rapamycin C51H79NO13 914.2 p70S6K Powell D.J. (2003) Mol. Cell Biol. 23 7794 Braun W. (1995) FASEB J. 9 63
Resveratrol C14H12O3 228.2 cyclo-oxygenase 1 Lin H.Y. (2002) J. Urol. 168 748 Klabunde T. (2000) Nat. Struct. Biol. 7 312
Rigel TRAF6 Inhibitor C16H12ClF4N5O3S 465.81 TRAF6
RO-31-8220 C25H23N5O2S • CH4O3S 553.7 PKC Trapp J. (2006) J. Med. Chem. 49 7307-16 Powell D.J. (2003) Mol. Cell Biol. 23 7794
RO-3306 C₁₈H₁₃N₃OS₂ 351.5 Cdk1 Vassilev, L.T. (2006) Proc. Natl. Acad. Sci. USA 103 10660
Roscovitine C19H26N6O 354.5 CDK De Azevedo W.F. (1997) Eur. J. Biochem. 243 518 Meijer L. (1997) Eur. J. Biochem. 243 527
Rottlerin C30H28O8 516.5 PKC Villalba M. (1999) J. Immunol. 163 5813 Gschwendt M. (1994) Biochem. Biophys. Res. Commun. 199 93
Ruxolitinib (INCB18424) C17H18N6 306.37 JAK Lawrence J Wilson (2010) Expert Opinion on Therapeutic Patents May 20(5) 609-623
Saracatinib (AZD0530) C27H32ClN5O5 542.03 Src H Laurent (2006) J. Med. Chem. 49(22) 6465-6488
SB-202190 C20H14FN3O 331.3 p38 MAPK Davies S.P. (2000) Biochem. J. 351 95 Ajizian S.J. (1999) J. Infect. Dis. 179 939
SB-203580 C21H16N3OSF 377.4 p38 MAPK Powell D.J. (2003) Mol. Cell Biol. 23 7794 Davies S.P. (2000) Biochem. J. 351 95
SB-216763 C19H12Cl2N2O2 371.22 GSK3 Coghlan (2000) Chem.Biol. 7 793 Liang (2006) J.Biol.Chem. 282 3904
SB-415286 C16H10ClN3O5 359.73 GSK3 Coghlan (2000) Chem.Biol. 7 793 Cross (2001) J.Neurochem. 77 94
SB-431542 C22H16N4O3 · xH2O 384.39 ALK Inman et al (2002) Mol.Pharmacol. 62 65
SB-505124 C20H21N3O2 · xHCl · yH2O 335.40 ALK Byfield (2004) Mol.Pharmacol. 65 744
SB-590885 C27H27N5O2 453.54 B-Raf King (2006) Cancer Res. 66 11100
SB-747651A C16H22N8O 342.40 Naqvi (2012) Biochem. J. 441 (347–357)
SC514 ( IKK-2 Inhibitor) C9H8N2OS2 224.3 IKK2 Baxter A. (2004) Bioorg. Med. Chem. Lett. 14 2817 Kishore N. (2003) J. Biol. Chem. 278 32861
SGK-Sanofi-14i C18H15ClN6O3S 430,.87 SGK Halland, N (2015) ACS Medicinal Chemistry Letters 6 73-78

Pages

XLSCSVXLSCSV

Do you need any help? Please get in touch and we’ll be happy to lend a hand.